Oncology Active Pharmaceutical Ingredient (API) Market Outlook:
Oncology Active Pharmaceutical Ingredient Market size was over USD 40.56 billion in 2025 and is anticipated to cross USD 66.7 billion by 2035, growing at more than 5.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of oncology active pharmaceutical ingredient is estimated at USD 42.42 billion.
The growth of the market can be estimated to be the higher prevalence of cancer owing to unhealthy lifestyles and genetic disorders across the globe. Based on the report published by World Health Organization (WHO) it was stated that in 2020, approximately 10 million deaths were caused by cancer around the world. Furthermore, the rising awareness about the effectiveness of active pharmaceutical ingredients (API) on targeted cancerous cells is also anticipated to propel their demand in the upcoming years.
Global oncology active pharmaceutical ingredient (API) market trends such as growing consumption of pain relievers and ongoing multiple Research & Development activities pertaining to the development of novel anti-cancer drugs are further estimated to influence the market growth positively during the forecast period. Other than the aforementioned factors, the recent development by biomarkers to increase the effectiveness of active pharmaceutical ingredients on targeted cancerous cells while minimizing the effect on non-cancerous cells is also anticipated to proliferate the market for growth and expansion. Also, rising awareness among patients regarding the side effects associated with chemotherapy treatments is projected to augment the demand for biologically active drugs with lower dosages coupled with technological advancements to reduce the pain from chronic diseases among patients are other factors that are estimated to bring lucrative growth opportunities for market growth. It is observed that 1 out of 5 individuals which is equivalent to 20 million people in the United States suffers from chronic pain. Thereby, all these factors are projected to fuel the market growth over the forecast period.
Key Oncology Active Pharmaceutical Ingredient (API) Market Insights Summary:
Regional Highlights:
- The oncology active pharmaceutical ingredient market in North America is projected to dominate with the largest revenue share by 2035, driven by the mounting prevalence of cancer and a rapidly expanding geriatric population.
- Asia Pacific is expected to secure a notable share along with a steady CAGR through 2026–2035, supported by a large patient pool and rising healthcare expenditure.
Segment Insights:
- In the oncology active pharmaceutical ingredient market, the breast cancer segment is projected to secure the largest share by 2035, propelled by rising cases of breast cancer.
- The synthetic oncology APIs segment is expected to account for the highest market share by 2035, fueled by low manufacturing costs and simpler production processes.
Key Growth Trends:
- Increasing Consumption of Tobacco and Cigarettes
- Mounting Number of Geriatric Population
Major Challenges:
- Lack of Awareness among the Global Population
- Possibilities of Side-Effects
Key Players: MPSi Medical Physics Services Intl., Limited, Medical Physics Consultants, Inc., Krueger-Gilbert Health Physics, Inc., Radiation Safety & Control Services, Inc, Alyzen Medical Physics, Versant Medical Physics & Radiation Safety, Alliance Medical Physics LLC, West Physics Consulting, LLC, Radiation Services, Inc., Jaeger Corporation, Apex Physics Partners.
Global Oncology Active Pharmaceutical Ingredient (API) Market Forecast and Regional Outlook:
Market Size & Growth Projections:
- 2025 Market Size: USD 40.56 billion
- 2026 Market Size: USD 42.42 billion
- Projected Market Size: USD 66.7 billion by 2035
- Growth Forecasts: 5.1% CAGR (2026-2035)
Key Regional Dynamics:
- Largest Region: North America
- Fastest Growing Region: Asia Pacific
- Dominating Countries: United States, China, India, Germany, Switzerland
- Emerging Countries: China, India, South Korea, Japan, Brazil
Last updated on : 25 February, 2026
Oncology Active Pharmaceutical Ingredient (API) Market - Growth Drivers and Challenges
Growth Drivers
- Increasing Consumption of Tobacco and Cigarettes - As of 2020, about 12 out of 100 adults in the United States were noticed to be smoking cigarettes. Tobacco and cigarettes are the leading cause of cancer and they are still highly consumed by adults. The prevalence of tobacco and cigarette consumption is generally high in every region. Hence, such a mounting consumption is estimated to foster the growth of the market during the forecast period.
- Mounting Number of Geriatric Population – As people start to age, their body weakens and body organs start to deteriorate. As a result, they are more prone to cancer and other chronic diseases. According to the data released by the World Bank, the number of geriatrics was noticed to be 747,238,580 in 2021 around the world.
- Growing Healthcare Expenditure per Capita – With the growing economies, the spending capacity of individuals also rose during the recent period. As a result, the spending on health and fitness increased, subsequently increasing the sales of oncology active pharmaceutical ingredients in the assessment period. Hence, the increased healthcare expenditure is attributed to generating significant revenue in the next years. A report from World Health Organization (WHO) stated that global spending on health increased steadily throughout the period of 2000 to 2018, ultimately reaching approximately USD 8 trillion or 10% of global GDP.
- Higher Prevalence of Medication Errors- For instance, reports of medication errors received by the U.S. FDA were stated to be more than 100,000 in 2019 in the United States region.
Challenges
- Lack of Awareness among the Global Population – Although oncology active pharmaceutical ingredient (API) has many added benefits such as fast recovery, greater positive impact on cells, and enhanced patient experience, the awareness level about oncology active pharmaceutical ingredient among the general patient population is considered very less. As a result, the adoption rate of oncology active pharmaceutical ingredients (API) is projected to slow down during the forecast period.
- Possibilities of Side-Effects
- Higher Price Associated with the Manufacturing Procedure
Oncology Active Pharmaceutical Ingredient (API) Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2025 |
|
Forecast Year |
2026-2035 |
|
CAGR |
5.1% |
|
Base Year Market Size (2025) |
USD 40.56 billion |
|
Forecast Year Market Size (2035) |
USD 66.7 billion |
|
Regional Scope |
|
Oncology Active Pharmaceutical Ingredient (API) Market Segmentation:
Type of Cancer Segment Analysis
The global oncology active pharmaceutical ingredient (API) market is segmented and analyzed for demand and supply by type of cancer into breast, cervical, lung, liver, colorectal, and others. Amongst these segments, the breast cancer segment is projected to acquire the largest market share over the forecast period on the back of rising cases of breast cancer. World Health Organization (WHO) showed that in 2020 around 2.26 million cases of breast cancer were diagnosed across the globe. The rising number of deaths owing to breast cancer along with the increased difficulties among patients owing to breast cancer is estimated to increase the demand for oncology active pharmaceutical ingredients in the next few years.
APIs Segment Analysis
The global oncology active pharmaceutical ingredient (API) market is also segmented and analyzed for demand and supply by synthesis type into synthetic oncology APIs, and biotech oncology APIs. Out of these two segments, the synthetic oncology APIs segment is anticipated to garner the highest market share owing to the high advantages and benefits offered by them. Low cost for manufacturing synthetic oncology active pharmaceutical ingredients owing to the fewer costs of the raw materials used is considered to be the major factor for segment expansion. Furthermore, the easy process of manufacturing coupled with less complex processes is another factor that is projected to create a positive outlook for segment growth during the analysis period.
Our in-depth analysis of the global market includes the following segments:
|
By APIs |
|
|
By Synthesis Type |
|
|
By Manufacturing Type |
|
|
By Type of Cancer |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Oncology Active Pharmaceutical Ingredient (API) Market - Regional Analysis
North American Market Insights
North America industry is estimated to account for largest revenue share by 2035. The growth of the market in the region is accented to the mounting prevalence of cancer. Data published by the Centers for Disease Control and Prevention showed that in 2019, 1,752,725 new cases of cancer were diagnosed while 599,589 people lost their lives due to cancer in a similar year in the United States. Additionally, the rising geriatric population and developing healthcare infrastructure are further expected to hike the growth of the market over the forecast period. Figures provided by the World Bank showed that in 2021, the number of geriatrics in the USA reached 56,545,938. Further, the presence of a strong healthcare network in the region, along with the availability of supportive policies by the regulatory bodies are also anticipated to contribute to the market growth in the region.
APAC Market Market Insights
On the other hand, the Asia Pacific oncology active pharmaceutical ingredient (API) is also attributed to garnering a notable market share including a steady CAGR. The presence of a large pool of patients in the region, along with the rising outflow and inflow of patients in the hospitals on a daily basis are projected to be the major factors for market expansion in the region. In addition, the rapid growth in the healthcare industry in the region, especially in China, India, and Japan, and the surge of healthcare expenditure is also anticipated boost market growth during the forecast period.
Oncology Active Pharmaceutical Ingredient (API) Market Players:
- Merck & Co. Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- Abbott Laboratories
- Sun Pharmaceutical Industries Ltd.
- Novartis AG
- Mylan N.V.
- GSK plc
- AbbVie Inc.
- Teva Pharmaceutical Industries Ltd.
- Eli Lilli and Company
Recent Developments
- AbbVie Inc. conducted a survey, Emotional Impact Report, and released the findings from it. This survey included more than 300 chronic lymphocytic leukemia patients that grow out of blood cancer. The survey also offered mental and emotional support to patients living with slow-growing blood cancer.
- Abbott Laboratories to emerge in a study published in the Lancet Neurology to elaborate on the capability of two blood-based biomarkers to predict the results from traumatic brain injury (TBI) and inform treatment interventions.
- Report ID: 4213
- Published Date: Feb 25, 2026
- Report Format: PDF, PPT
- Explore a preview of key market trends and insights
- Review sample data tables and segment breakdowns
- Experience the quality of our visual data representations
- Evaluate our report structure and research methodology
- Get a glimpse of competitive landscape analysis
- Understand how regional forecasts are presented
- Assess the depth of company profiling and benchmarking
- Preview how actionable insights can support your strategy
Explore real data and analysis
Frequently Asked Questions (FAQ)
Oncology Active Pharmaceutical Ingredient (API) Market Report Scope
Free Sample includes current and historical market size, growth trends, regional charts & tables, company profiles, segment-wise forecasts, and more.
Connect with our Expert
Copyright @ 2026 Research Nester. All Rights Reserved.
